id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-D-0094-0034,FDA,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory
Committee Members, and Food and Drug Administration Staff: Public
Availability of Advisory Committee Members’ Financial Interest
Information and Waivers",Other,Guidance,2014-03-31T04:00:00Z,2014,3,2014-03-31T04:00:00Z,,2024-11-07T23:07:11Z,,1,0,0900006481691d05
FDA-2002-D-0094-0033,FDA,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory
Committee Members, and Food and Drug Administration Staff: Public
Availability of Advisory Committee Members’ Financial Interest
Information and Waivers; Availability",Notice,Notice of Availability,2014-03-31T04:00:00Z,2014,3,2014-03-31T04:00:00Z,,2014-03-31T14:12:23Z,2014-06997,0,0,09000064816912ef
FDA-2002-D-0094-0032,FDA,FDA-2002-D-0094,"Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers",Other,Guidance,2012-03-09T05:00:00Z,2012,3,2012-03-09T05:00:00Z,,2024-11-07T22:28:07Z,,1,0,0900006480fd2db6
FDA-2002-D-0094-0031,FDA,FDA-2002-D-0094,"Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers: Availability",Notice,Notice of Availability,2012-03-09T05:00:00Z,2012,3,2012-03-09T05:00:00Z,,2012-03-09T15:34:01Z,2012-05776,0,0,0900006480fd2859
FDA-2002-D-0094-0022,FDA,FDA-2002-D-0094,"Appendix A - "" RJReynolds Letter to FDA, June 30, 2010"" - [R.J. Reynolds Tobacco Company - Comment] re FDA-2002-D-0094-0018",Supporting & Related Material,C-Comment (Supporting and Related Material),2010-11-05T04:00:00Z,2010,11,,,2012-03-24T19:34:22Z,,0,0,0900006480b6d38d
FDA-2002-D-0094-0023,FDA,FDA-2002-D-0094,"Appendix C - ""FDAAC August 30, 2010"" - [R.J. Reynolds Tobacco Company - Comment] re FDA-2002-D-0094-0018",Supporting & Related Material,C-Comment (Supporting and Related Material),2010-11-05T04:00:00Z,2010,11,,,2010-11-05T21:04:14Z,,0,0,0900006480b82f6d
FDA-2002-D-0094-0007,FDA,FDA-2002-D-0094,"Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Availability",Notice,NAD-Notice of Availability of Data,2010-04-22T04:00:00Z,2010,4,2010-04-22T04:00:00Z,2010-06-22T03:59:59Z,2010-04-22T14:20:21Z,2010-09313,0,0,0900006480add0fe
FDA-2002-D-0094-0008,FDA,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Draft Guidance",Other,GDL-Guidance (Supporting and Related Materials),2010-04-22T04:00:00Z,2010,4,2010-04-22T04:00:00Z,2010-06-22T03:59:59Z,2024-11-12T04:51:25Z,,1,0,0900006480add437
FDA-2002-D-0094-0006,FDA,FDA-2002-D-0094,"Draft Guidance on Disclosure of Conflicts of Interest for Special Gqvernment Employees Participating in FDA Product Specific Advisory Committees, January 2002",Other,GDL-Guidance (Supporting and Related Materials),2009-02-24T05:00:00Z,2009,2,,,2010-08-06T20:53:14Z,,0,0,090000648048e47c
FDA-2002-D-0094-0004,FDA,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability",Notice,NAD-Notice of Availability of Data,2008-08-05T04:00:00Z,2008,8,2008-08-05T04:00:00Z,,2024-11-12T04:15:49Z,E8-17999,1,0,09000064806aed88
FDA-2002-D-0094-0005,FDA,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff:  Public Availability of Advisory Committee Members' Financial Interest Information and Waivers, August 2008",Other,GDL-Guidance (Supporting and Related Materials),2008-08-05T04:00:00Z,2008,8,2008-08-05T04:00:00Z,,2010-08-06T23:48:05Z,,0,0,09000064806af63a
FDA-2002-D-0094-0002,FDA,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers, October 2007",Other,GDL-Guidance (Supporting and Related Materials),2007-10-31T04:00:00Z,2007,10,,,2010-08-06T23:49:08Z,,0,0,090000648048e4a2
FDA-2002-D-0094-0003,FDA,FDA-2002-D-0094,"Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Availability",Notice,NAD-Notice of Availability of Data,2007-10-31T04:00:00Z,2007,10,2007-10-31T04:00:00Z,2008-01-01T04:59:59Z,2010-08-06T23:52:22Z,,0,0,090000648048e4a5
FDA-2002-D-0094-0001,FDA,FDA-2002-D-0094,Draft Guidance on Disclosure of Conflicts of Interest for Special Government Employees Participating in FDA Product Specific Advisory Committees; Availability,Notice,NAD-Notice of Availability of Data,2002-02-12T05:00:00Z,2002,2,2002-02-12T05:00:00Z,2002-03-15T04:59:59Z,2010-08-06T20:48:12Z,,0,0,090000648048e44e